Professional Marketing briefs: May 2013

AstraZeneca, J&J enter cancer collaborations
AstraZeneca, J&J enter cancer collaborations

Bristol Myers-Squibb will shut now-subsidiary Amylin's San Diego site by 2014. The closing will affect 420 employees who work in R&D, commercial, manufacturing, corporate and administrative positions. BMS also is merging its Ohio workforce with that of Amylin's, a change that will have an impact on the staff who fill Amylin's 400 in-field sales and medical roles. BMS bought Amylin in August 2012, paying $5.3 billion and assuming $1.7 billion in debt.

AstraZeneca announced 3,900 layoffs in March, which will be spread out over the next three years. Sales and adminis­trative positions are among the jobs to be cut. A spokesman told MM&M the bulk of the losses will be in Europe and that some layoffs were previously known about internally.

Accenture's latest numbers indicate that pitching on a doctor's turf will increasingly mean working with fewer clinician owners, reported Amednews. Accenture found “36% of practicing physicians will hold a practice ownership stake by the end of 2013, a decline from 57% in 2000.” Amednews said to also expect high turnover at these businesses because no ownership stake to sell, means an easier exit.
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


Investment in healthcare IT stands at an all-time high. The government has spent billions to promote EHR adoption. Yet the physician wish list is a mile long, while hospitals and patients are not where they need to be. To peel back the layers of what we've all been waiting for in the Great Data Capture of the 21st Century, and to review the changes enabling the healthcare data ecosystem to coexist, MM&M presents this e-Book. Click here.


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.